Gianrico Farrugia, President and CEO at Mayo Clinic, shared a post on LinkedIn:
“Through Mayo Clinic Platform, researchers will now have accelerated access to de-identified cancer data that has been standardized to allow for more rapid analysis of tumor characteristics, biomarkers, staging, treatments, progression, and outcomes.
Embedded within the Platform’s longitudinal, multi-modal data architecture, the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) framework will transform the usual multi-year, time-intensive process for researchers to develop new cancer therapies and advance cures faster than ever before. Learn more.”
You can also read:
Gianrico Farrugia Recognized Among The 100 Most Influential CEOs in Oncology in 2025
